ArticleKorean journal of urology2012
Benign prostatic hyperplasia: from bench to clinic.
Article in Korean journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 10 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2022Pooled it
- Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2021Pooled it
- Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2019Pooled it
- Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2019Pooled it
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2017Pooled it
- Pooled it
- Establishment and validation of a risk scoring model for predicting the risk of bladder stones in patients with benign prostatic hyperplasia.Frontiers in medicine · 2026Article
- Midline-1 inhibited high glucose-induced epithelial-mesenchymal transition, fibrosis and inflammation through WNT/β-catenin signaling in benign prostatic hyperplasia.Frontiers in endocrinology · 2025Article
- Obstructive kidney disease: which is the culprit, prostate or stone?Journal of nephrology · 2024Article
- IL-6 Signaling Link between Inflammatory Tumor Microenvironment and Prostatic Tumorigenesis.Analytical cellular pathology (Amsterdam) · 2022Review
- Tissue Kallikrein Protects Rat Prostate against the Inflammatory Damage in a Chronic Autoimmune Prostatitis Model via Restoring Endothelial Function in a Bradykinin Receptor B2-Dependent Way.Oxidative medicine and cellular longevity · 2022Article
- Article
- The association of benign prostatic hyperplasia with lower urinary tract stones in adult men: A retrospective multicenter study.Asian journal of urology · 2018Article
- Metabolic syndrome is predictive of lower urinary tract symptom improvement after holmium laser enucleation of the prostate for benign prostatic obstruction.International urology and nephrology · 2017Article
- Inhibition of chronic prostate inflammation by hyaluronic acid through an immortalized human prostate stromal cell line model.PloS one · 2017Article
- Obesity as a Risk Factor for Prostatic Enlargement: A Retrospective Cohort Study in Korea.International neurourology journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is a prevalent disease, especially in old men, and often results in lower urinary tract symptoms (LUTS). This chronic disease has important care implications and financial risks to the health care system. LUTS are caused not only by mechanical prostatic obstruction but also by the dynamic component of obstruction. The exact etiology of BPH and its consequences, benign prostatic enlargement and benign prostatic obstruction, are not identified. Various theories concerning the causes of benign prostate enlargement and LUTS, such as metabolic syndrome, inflammation, growth factors, androgen receptor, epithelial-stromal interaction, and lifestyle, are discussed. Incomplete overlap of prostatic enlargement with symptoms and obstruction encourages focus on symptoms rather than prostate enlargement and the shifting from surgery to medicine as the treatment of BPH. Several alpha antagonists, including alfuzosin, doxazosin, tamsulosin, and terazosin, have shown excellent efficacy without severe adverse effects. In addition, new alpha antagonists, silodosin and naftopidil, and phosphodiesterase 5 inhibitors are emerging as BPH treatments. In surgical treatment, laser surgery such as photoselective vaporization of the prostate and holmium laser prostatectomy have been introduced to reduce complications and are used as alternatives to transurethral resection of the prostate (TURP) and open prostatectomy. The status of TURP as the gold standard treatment of BPH is still evolving. We review several preclinical and clinical studies about the etiology of BPH and treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.